CN119365206A - 用于治疗血管生成性眼病的延长的高剂量vegf拮抗剂方案 - Google Patents

用于治疗血管生成性眼病的延长的高剂量vegf拮抗剂方案 Download PDF

Info

Publication number
CN119365206A
CN119365206A CN202380025696.0A CN202380025696A CN119365206A CN 119365206 A CN119365206 A CN 119365206A CN 202380025696 A CN202380025696 A CN 202380025696A CN 119365206 A CN119365206 A CN 119365206A
Authority
CN
China
Prior art keywords
weeks
fusion protein
dose
vegf receptor
receptor fusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380025696.0A
Other languages
English (en)
Chinese (zh)
Inventor
R·L·维蒂
A·J·贝利纳
K·楚
F·阿斯姆斯
S·C·达席尔瓦莱亚尔
T·艾辛
K·D·里滕豪斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Healthcare LLC
Regeneron Pharmaceuticals Inc
Original Assignee
Bayer Healthcare LLC
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA3190726A external-priority patent/CA3190726A1/en
Application filed by Bayer Healthcare LLC, Regeneron Pharmaceuticals Inc filed Critical Bayer Healthcare LLC
Publication of CN119365206A publication Critical patent/CN119365206A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202380025696.0A 2022-03-15 2023-03-14 用于治疗血管生成性眼病的延长的高剂量vegf拮抗剂方案 Pending CN119365206A (zh)

Applications Claiming Priority (21)

Application Number Priority Date Filing Date Title
US202263319865P 2022-03-15 2022-03-15
US63/319,865 2022-03-15
US202263404511P 2022-09-07 2022-09-07
US63/404,511 2022-09-07
US202263404889P 2022-09-08 2022-09-08
US63/404,889 2022-09-08
US202263411589P 2022-09-29 2022-09-29
US63/411,589 2022-09-29
US202263412158P 2022-09-30 2022-09-30
US63/412,158 2022-09-30
US202263421296P 2022-11-01 2022-11-01
US63/421,296 2022-11-01
US202263434918P 2022-12-22 2022-12-22
US63/434,918 2022-12-22
US202363444470P 2023-02-09 2023-02-09
US63/444,470 2023-02-09
US202363447577P 2023-02-22 2023-02-22
CA3190726A CA3190726A1 (en) 2022-03-15 2023-02-22 Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders
US63/447,577 2023-02-22
CA3190726 2023-02-22
PCT/US2023/015223 WO2023177689A1 (en) 2022-03-15 2023-03-14 Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders

Publications (1)

Publication Number Publication Date
CN119365206A true CN119365206A (zh) 2025-01-24

Family

ID=85703566

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380025696.0A Pending CN119365206A (zh) 2022-03-15 2023-03-14 用于治疗血管生成性眼病的延长的高剂量vegf拮抗剂方案

Country Status (13)

Country Link
US (1) US20230295266A1 (enExample)
EP (1) EP4245313A1 (enExample)
JP (1) JP2023135645A (enExample)
KR (1) KR20230135012A (enExample)
CN (1) CN119365206A (enExample)
AU (2) AU2023234355A1 (enExample)
CA (1) CA3254467A1 (enExample)
CL (2) CL2024002718A1 (enExample)
IL (1) IL315347A (enExample)
JO (1) JOP20240198A1 (enExample)
MX (1) MX2024011132A (enExample)
TW (1) TW202400215A (enExample)
WO (1) WO2023177689A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20240329A1 (es) 2019-06-05 2024-02-27 Regeneron Pharma Dispositivos y metodos para administracion de dosis de precision
FI4185318T3 (fi) 2021-05-17 2025-10-13 Regeneron Pharma Pitkäaikaisia, suuren annoksen VEGF-antagonistihoitoja angiogeenisten silmäsairauksien hoitoon
US12649031B2 (en) 2021-09-08 2026-06-09 Regeneron Pharmaceuticals, Inc. Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
CN121712520A (zh) 2023-06-23 2026-03-20 瑞泽恩制药公司 用于治疗血管生成性眼病的延长的高剂量vegf拮抗剂方案
WO2025166292A1 (en) * 2024-02-02 2025-08-07 Kodiak Sciences Inc. Methods of treating eye disorders
CN117805397A (zh) * 2024-02-29 2024-04-02 军科正源（北京）药物研究有限责任公司 检测游离vegf的方法
WO2026019840A1 (en) * 2024-07-16 2026-01-22 4D Molecular Therapeutics Inc. Methods for treating diabetic macular edema with adeno-associated virus
KR20260096819A (ko) * 2024-12-13 2026-06-24 리제너론 파아마슈티컬스, 인크. 망막 정맥 폐쇄에 속발하는 혈관신생 눈 장애의 치료를 위한 연장된 고용량 vegf 길항제 레지먼

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
AR046510A1 (es) 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo
ES2381014T3 (es) 2004-06-08 2012-05-22 Chengdu Kanghong Biotechnologies Co., Ltd. Proteína quimérica inhibidora de la angiogénesis y el uso
CN100502945C (zh) 2006-03-31 2009-06-24 成都康弘生物科技有限公司 Vegf受体融合蛋白在治疗眼睛疾病中的应用
KR20200093621A (ko) * 2017-11-30 2020-08-05 리제너론 파아마슈티컬스, 인크. 혈관형성 눈 장애를 치료하기 위한 vegf 길항제의 용도
IL318292A (en) 2017-12-13 2025-03-01 Regeneron Pharma Devices and methods for administering precise doses
RS67656B1 (sr) 2018-05-10 2026-02-27 Regeneron Pharma Formulacije koje sadrže visoke koncentracije fuzionog proteina vegf receptora
PE20240329A1 (es) 2019-06-05 2024-02-27 Regeneron Pharma Dispositivos y metodos para administracion de dosis de precision
AU2020326243A1 (en) * 2019-08-06 2022-02-17 F. Hoffmann-La Roche Ag Personalized treatment of ophthalmologic diseases
CN114867487A (zh) * 2019-11-25 2022-08-05 加利福尼亚大学董事会 用于眼内新生血管的长效vegf抑制剂
US11944663B2 (en) * 2020-06-18 2024-04-02 Chengdu Kanghong Biotechnologies Co. Ltd. Method for treating angiogenic eye disorders using VEGF antagonists
FI4185318T3 (fi) * 2021-05-17 2025-10-13 Regeneron Pharma Pitkäaikaisia, suuren annoksen VEGF-antagonistihoitoja angiogeenisten silmäsairauksien hoitoon

Also Published As

Publication number Publication date
JP2023135645A (ja) 2023-09-28
JOP20240198A1 (ar) 2024-09-11
CA3254467A1 (en) 2023-09-21
CL2025001801A1 (es) 2025-09-26
MX2024011132A (es) 2025-01-09
EP4245313A1 (en) 2023-09-20
CL2024002718A1 (es) 2025-02-21
IL315347A (en) 2024-11-01
TW202400215A (zh) 2024-01-01
WO2023177689A1 (en) 2023-09-21
AU2023234355A1 (en) 2024-09-19
KR20230135012A (ko) 2023-09-22
US20230295266A1 (en) 2023-09-21
AU2023201635A1 (en) 2023-10-05

Similar Documents

Publication Publication Date Title
US11071780B2 (en) Methods and formulations for treating vascular eye diseases using aflibercept and nesvacumab
US20230295266A1 (en) Extended, High Dose VEGF Antagonist Regimens for Treatment of Angiogenic Eye Disorders
CN119136823A (zh) 用于治疗血管生成性眼病的延长的高剂量vegf拮抗剂方案
AU2022275786C1 (en) Extended, high dose VEGF antagonist regimens for treatment of angiogenic eye disorders
EP4480491A1 (en) Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders
HK40099475A (en) Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders
CA3190726A1 (en) Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders
HK40119109A (en) Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders
CA3190733A1 (en) Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders
HK40099476A (en) Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders
HK1241908A1 (en) Methods and formulations for treating vascular eye diseases

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination